Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Transitional Cell

Explore clinical trials studying Carcinoma, Transitional Cell. Study availability and eligibility vary by location and protocol.

417 public trials 125 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Transitional Cell trial results

Active, Not Recruiting

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814

Conditions
Carcinoma, Carcinoma, Transitional Cell, Metastatic Urothelial Carcinoma, +4 more
Locations
  • Moores Cancer Center ( Site 3028) La Jolla, California, United States
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3045) Orange, California, United States
  • UCSF Medical Center at Mission Bay ( Site 3044) San Francisco, California, United States
  • Anschutz Cancer Pavilion ( Site 3017) Aurora, Colorado, United States
View all 47 locations
View Trial Details
Active, Not Recruiting

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03170960

Conditions
Adenocarcinoma, Adnexal Diseases, Breast Diseases, +68 more
Locations
  • Exelixis Clinical Site #53 Gilbert, Arizona, United States
  • Exelixis Clinical Site #18 Phoenix, Arizona, United States
  • Exelixis Clinical Site #1 Duarte, California, United States
  • Exelixis Clinical Site #20 La Jolla, California, United States
View all 124 locations
View Trial Details
Active, Not Recruiting

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

NCT06632951

Conditions
Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations
  • Highlands Oncology Group - Springdale /ID# 270290 Springdale, Arkansas, United States
  • University of California San Francisco - Mission Bay /ID# 270289 San Francisco, California, United States
  • Yale University School of Medicine /ID# 270449 New Haven, Connecticut, United States
  • Medical Oncology Hematology Consultants /ID# 271347 Newark, Delaware, United States
View all 37 locations
View Trial Details
Active, Not Recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

NCT00365157

Conditions
Advanced Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +9 more
Locations
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope Antelope Valley Lancaster, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 26 locations
View Trial Details
Active, Not Recruiting

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526

Conditions
Adenocarcinoma, Adenoid Cystic Carcinoma, Adnexal Diseases, +94 more
Locations
  • Highlands Oncology Group Springdale, Arkansas, United States
  • University of California at Davis Davis, California, United States
  • The Oncology Institute of Hope and Innovation Downey, California, United States
  • City of Hope Cancer Center Duarte, California, United States
View all 37 locations
View Trial Details

Related conditions